Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

INSANE: 68 | Vintage Vibes

COVID updates: All the coronavirus news you need in the one place — as it happened

Get up to speed on all the coronavirus news from across Australia.

ABC News

Michael Hiltzik: The government could force a price cut for this prostate cancer drug by as much as 80%. Why hasn't it acted?

Xtandi, a wonder drug for prostate cancer, was developed at UCLA with substantial funding from the taxpayers through the Pentagon and the National Institutes of Health.

Los Angeles Times

Expert Ratings For Pfizer

Analysts have provided the following ratings for Pfizer (NYSE:PFE) within the last quarter:

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Where Pfizer Stands With Analysts

Over the past 3 months, 11 analysts have published their opinion on Pfizer (NYSE:PFE) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Benzinga

Japan OKs Pfizer COVID-19 oral pills amid surging infections

Japan has granted fast-track approval to U.S. drug maker Pfizer Inc.’s COVID-19 pill as the country struggles to slow fast-spreading omicron infections

The Independent UK

A COVID vaccine for children under five is one step closer. Here are five key questions that need answering

Children under five in the US could be getting vaccinated against COVID-19 as soon late February. Here's what we know so far about the jab, and what might happen next.

ABC News

Under pressure GlaxoSmithKline promises ‘landmark’ year as its outshone by Pfizer

GlaxoSmithKline remained under pressure today after so-so results that drew unfavourable comparisons with US rival Pfizer.

Evening Standard

Read news from The Economist, FT, and more,
with one subscription

How effective are the Pfizer, AstraZeneca and Moderna vaccines against Omicron?

Booster jabs provide up to 70 per cent protection, study finds

The Independent UK

Pfizer sees Covid-19 drug sales topping $50bn in 2022

NEW YORK - Pfizer forecast more than $50 billion in 2022 sales for its Covid-19 vaccine and therapeutic on Tuesday as the pharmaceutical giant reported a more than doubling of annual profits on strong sales of its innoculation.

Bangkok Post

A new top-selling medicine: Pfizer's COVID vaccine

Almost $37 billion this year, and another $32 billion coming next year.

Axios

Mid-Day Market Update: Pfizer Sales Miss Expectations; Teradata Shares Spike Higher

US stocks remained mostly higher on Tuesday, while the S&P 500 traded lower by 0.1%.

Benzinga

Putting big pharma in charge of global vaccine rollout was a big mistake

Covid has made it clear: the likes of Pfizer, in thrall to shareholders, only really care about their huge profits, says the director of Global Justice Now

The Guardian - UK

Pfizer accused of pandemic profiteering as profits double

Drugmaker makes $37bn in vaccine sales and predicts bumper year ahead from Covid jabs and pill

The Guardian - UK

The Daily Biotech Pulse: Pfizer, Amgen Shares Slip On Earnings, Editas Terminates Chief Medical Officer, Biogen Licenses Preclinical Rheumatoid Arthritis Biosimilar

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Pfizer Q4 Sales Lag Consensus; Forecasts $54B In FY22 From COVID-19 Vaccine, Treatment Pill

Pfizer Inc (NYSE: PFE) has reported

Benzinga

Pfizer: Q4 Earnings Insights

Pfizer (NYSE:PFE) reported its Q4 earnings results on Tuesday, February 8, 2022 at 06:45 AM. Here's what investors need to know about the announcement.

Pedestrian.tv

We’ve Officially Got A Fourth Vaccine, So Here’s Everything You Need To Know About Novavax

Say hello to Ms Novavax!

Benzinga

5 Stocks To Watch For February 8, 2022

Some of the stocks that may grab investor focus today are: Wall Street expects Pfizer Inc. (NYSE: PFE) to report quarterly earnings at $0.87 per share on revenue of $24.20 billion before the opening bell. Pfizer shares rose 1.7% to $54.10 in after-hours trading.

Get all your
news in one place.

100's of premium titles.
One news app.

The Independent UK

Pfizer set for record vaccine revenue as world’s dose-sharing initiative runs out of cash

Pfizer’s Covid vaccine has become one of the most lucrative drugs in history

Benzinga

Earnings Scheduled For February 8, 2022

Companies Reporting Before The Bell • Pfizer (NYSE:PFE) is likely to report quarterly earnings at $0.87 per share on revenue of $24.20 billion.

The Guardian - UK

Ofgem admits failings over energy regulation, and warns Ukraine conflict would push bills higher – as it happened

Rolling coverage of the latest economic and financial news

The Guardian - AU

Covid live: Italy and Spain to ease mask mandate; UK records 66,183 new cases – as it happened

Italy and Spain relax rules on wearing masks in outdoor spaces; UK records 314 Covid-related deaths

The Conversation

What's the difference in protection against Omicron between 2 doses and 3 doses of vaccine?

Australian Health Minister Greg Hunt said last week he expects the Australian Technical Advisory Group on Immunisation (ATAGI) to change the definition of “fully vaccinated” to three doses instead of two.

Benzinga

A Preview Of Pfizer's Earnings

Pfizer (NYSE:PFE) is set to give its latest quarterly earnings report on Tuesday, 2022-02-08. Here's what investors need to know before the announcement. Analysts estimate that Pfizer will likely report an Earnings Per Share (EPS) of $7.85.

Axios

Kids' vaccines create a new dilemma for federal officials

They'll have to decide whether to authorize shots for small children with incomplete data.

1 … 67 68 69 70

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Office for National Statistics

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.